Jilin Broadwell Pharmaceutical Co., LTD., established in April 2010, is a biochemical pharmaceutical Co., LTD., with the concept of maintaining human health, the core values of absorbing the essence of science and technology, and the sustainable development strategy based on two research and development platforms of biological and chemical drugs. The company focuses on biochemical pharmaceutical, focusing on the research, development, production and sales of cardiovascular and cerebrovascular, digestive and other drugs market layout. -- Chemotherapeutic drug r&d platform, adopting the following strategy, introducing and absorbing the first copy or pre-copy of foreign drugs with expired patents and patents to be expired, and being the first to be listed in China. There are more than 10 varieties under development, all of which are new drugs of more than 3 classes. -- Biomedical R&D platform, five biological agents developed, all with independent intellectual property rights, independently produced and sold biomedical and patented products, giving priority to the strategic emerging industries of domestic medicine.